Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues:
Grant	$ 1,033	$ 1,530	$ 488
Royalties and licenses	4,017	0	0
Sales and services	3,102	3,060	3,337
Total revenues	8,152	4,590	3,825
Operating costs and expenses:
Costs of revenues	811	1,950	2,043
Research and development	42,175	31,343	23,983
Acquired in-process research and development	45,000	24,013	209
General and administrative	24,219	20,132	9,987
Intangible amortization	845	1,157	2,345
(Gain) loss on contingent liabilities	(8,121)	0	0
Total costs and operating expenses	104,929	78,595	38,567
Loss from operations	(96,777)	(74,005)	(34,742)
Gain on sale of IgDraSol, net	0	69,274	0
Gain (loss) on derivative liabilities	5,520	(3,360)	0
Gain on marketable securities	27,193	0	0
Gain on trading securities	356	0	0
Gain (loss) on equity investments	435	(4,041)	0
Interest expense	(1,610)	(1,652)	(1,629)
Interest income	272	24	12
Loss on debt extinguishment	(222)	0	0
Loss before income tax expense	(64,833)	(13,760)	(36,359)
Income tax expense (benefit)	(896)	36,314	(1,702)
Net loss	(63,937)	(50,074)	(34,657)
Net loss attributable to noncontrolling interests	(3,014)	(4,263)	0
Net loss attributable to Sorrento	$ (60,923)	$ (45,811)	$ (34,657)
Net loss per share - basic and diluted per share attributable to Sorrento	$ (1.21)	$ (1.24)	$ (1.30)
Weighted-average shares used during period - basic and diluted per share attributable to Sorrento	50,360	36,909	26,679